A vaccine for breast cancer developed by St. Elizabeth Healthcare with Anixa Biosciences
Dana Hungler, Director of Marketing and Creative Design at St. Elizabeth Healthcare, shared a post
“We are proud to highlight a very exciting breakthrough in cancer prevention!
A groundbreaking therapy targeting a specific protein associated with breast cancer is now undergoing clinical trials. This innovative vaccine has been developed in partnership with Anixa Biosciences.
The aim is to program the immune system to recognize and combat potential cancer cells before they develop.
“This therapy has shown promising results in early studies, potentially transforming cancer prevention,” said Dr. Matthew Kurian, oncologist at St. Elizabeth Cancer Center.
The vaccine is currently being tested on high-risk individuals, including women who have undergone breast cancer treatment and are susceptible to recurrence, particularly those with triple-negative breast cancer.
While still in early stages, these trials represent a critical step toward offering patients and physicians a new tool in the fight against cancer.”
Source: Dana Hungler/LinkedIn